Stock Analysis of Zymeworks Inc. Common Stock (ZYME) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code ZYME
Close 25.88
Change -1.19 / 4.40 %
Volume 482648
Vol Change -87854.00 / 15.40 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthMild Bullish
Growth Index Poor Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Poor Stability Stock


Fundamental View of Zymeworks Inc. Common Stock


Highs/Lows of Zymeworks Inc. Common Stock
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week26.311.63 % 1.23 % 27.3324.7309-Jul-2606-Jul-26
Two Week24.157.16 % 3.01 % 27.3321.9109-Jul-2629-Jun-26
One Month22.8513.26 % 4.24 % 27.3321.9109-Jul-2629-Jun-26
Three Month26.321.67 % 11.13 % 29.7521.9127-Apr-2629-Jun-26
Six Months23.1711.70 % 8.74 % 29.7521.9127-Apr-2629-Jun-26
One year13.6689.46 % 20.62 % 29.7511.5127-Apr-2608-Aug-25
Two year9.24180.09 % 34.46 % 29.759.0327-Apr-2610-Apr-25
Five year36.8529.77 % 73.37 % 38.634.1121-Jul-2107-Sep-22


Technical View of Zymeworks Inc. Common Stock






Charts of Zymeworks Inc. Common Stock


Returns of Zymeworks Inc. Common Stock with Peers
Period / StockZYMEBCAXPGENIOVA
1 Week-1.63%-0.310%-5.67%-1.86%
1 Mth13.26%43.05%36.76%11.90%
3 Mth-1.67%36.88%27.88%14.32%
6mth11.70%61.06%15.90%72.65%
1 Year89.46%191.43%178.53%119.17%
2 Year180.09%-245.45%-45.63%
5 Years-29.77%--12.36%-84.12%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Zymeworks Inc. Common Stock with Peers
Ratio / StockZYMEBCAXPGENIOVA
PE-0.099-10.34-7.93-4.55
P/B0.0593.6770.102.24
ROA-20.51-33.60-143.44-38.31
ROE-59.71-35.55-1206.03-49.30
Debt To Equity12.930.00284.510.0058
Revenue-27110.00 K
135.53 %
0
%
9684.00 K
146.73 %
263502 K
60.60 %
Net Income-19663.53 M
15926.35 %
-137950.00 K
102.88 %
-429642.00 K
240.35 %
-390978.00 K
5.05 %


Technicals of Zymeworks Inc. Common Stock with Peers
Technical / StockZYMEBCAXPGENIOVA-
ADX16.3239.6229.2019.55
CMF0.1430.3070.137-0.170
MFI58.7579.3768.0368.78
RSI55.2466.0155.4452.88
MACD Abv SignalTrueTrueFalseTrue
Price Above 50 MATrueTrueTrueTrue-
Price Above 200 MATrueTrueTrueTrue-


About : Zymeworks Inc. Common Stock


Address : 108 Patriot Drive, Middletown, DE, United States, 19709
Tel : 302 274 8744
URL : https://www.zymeworks.com
Code : ZYME, ISIN : US98985Y1082, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 28_Apr_2017
Employee Count : 243

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.


Note : All Data Generated at the End of Trading Hours (EOD Data)